TMCnet News
Onco360® Named to Zydelig® (Idelalisib) Limited Distribution Network; Zydelig is Available Immediately for Order Through Onco360NEW YORK --(Business Wire)-- Onco360, the nation's fastest-growing independent Oncology Pharmacy and Clinical Support Services company, today announced that it has been selected to be part of the highly limited Specialty Pharmacy network of Zydelig (idelalisib) tablets. PharMerica Corporation (NYSE:PMC) is a significant investor in Onco360. Zydelig has been approved by The U.S. Food and Drug Administration (FDA) for the treatment of three different B-cell blood cancers1: 1. In combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy. 2. As monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies. 3. As monotherapy for patients with small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies. Oncology is the largest and fasted-growing segment of specialty drug expenditures:
"This selection is an important milestone in Onco360's strategy to offer an innovative, diversified portfolio of pharmacy and clinical solutions," said Vice Chairman of Onco360, Burt Zweigenhaft. "We have confidence in the potential of Zydelig to achieve a strong market share position and further bolster our leadership in the specialty oncology pharmacy market. This relationship also continues to enhance our mission of providing the highest level of support to those battling cancer and helping treat the unmet needs of thousands o people afflicted with life-threatening illness." "We are pleased to be among the select few companies working with Gilead Sciences to dispense Zydelig. This selection reflects Onco360's strong reputation in the marketplace and our Oncology Pharmacy team's commitment to fulfilling our patient-centric mission and values," said Senior Vice President of Trade Channel Strategy Relations for Onco360, Ron Bookman, J.D. Zydelig is immediately available for order through Onco360 and its network of OncoMed Pharmacies. Prescription orders can be placed by:
About Onco360®, Oncology Pharmacy Solutions: With executive offices in New York City, Onco360 (http://onco360.com) is the largest independent provider of Oncology Pharmacy services in the country. Onco360 was founded in 2003 as OncoMed, The Oncology Pharmacy, to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. The Company's clinical and dispensing model was developed specifically to meet the unique needs of oncology-treating physicians and their patients. Onco360 is advancing the continuum of oncology pharmaceutical care through patient advocacy, dispensing excellence, and the clinical experience and expertise that comes from its focus in oncology. Onco360 dispenses through its network JCAHO-accredited OncoMed Pharmacies. PharMerica Corporation (NYSE:PMC), a leading institutional pharmacy, specialty home infusion and hospital services company servicing healthcare facilities in the United States, is a significant investor in Onco360. The partnership between PharMerica and Onco360 creates the only national oncology pharmacy and care management platform in the country, with the unique ability to service the localized needs of community- and hospital based-oncologists.
|
